4.10 A Deep Dive into CheckMate 649 with Dr. Jeffrey Bien

OncologyMedicineHealth Policy
Written By Kerrington .

Today we sit down (in person!) with Dr. Jeff Bien of Stanford University to break down all the details -- from the methods to the statistical analysis to the conclusions -- of the CheckMate 649 trial, which pitted first-line nivolumab plus chemotherapy against chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma.

Kerrington .
Previous

4.11 CheckMate 274, PARADIGM-HF/Ernesto, POLO, & an AI Approach to Reducing Knee Pain
Next

4.09 Problems with the VISION Trial & Stool Transplant Plus Nivo for Metastatic Melanoma